SLC10A2 and metabolic dysfunction-associated steatohepatitis: The increase in BA fecal excretion in the atorvastatin-treated control group and both NASH groups paralleled repression of the apical sodium-dependent bile salt transporter (Slc10a2/Asbt), the major uptake transporter for the reabsorption of BA from the intestine lumen.